within Pharmacolibrary.Drugs.ATC.C;

model C09DA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 3.8333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.008333333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09DA09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) often used in combination with thiazide diuretics, such as chlorthalidone, for the treatment of hypertension. This fixed dose combination helps to lower blood pressure more effectively in patients with hypertension. The drug is approved for clinical use in several countries and is currently used in practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are primarily based on healthy adult volunteers (male and female), aged 18-65, under fasting conditions. Parameters reflect single-dose administration of the azilsartan medoxomil and chlorthalidone fixed dose combination. Most studies report PK data for the individual components; the following values are estimated based on typical exposures for a combination tablet equivalent to azilsartan medoxomil 40 mg and chlorthalidone 25 mg.</p><h4>References</h4><ol><li><p>Tsai, MC, et al., &amp; Vakilynejad, M (2016). Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With Stage 2 Hypertension. <i>Journal of clinical pharmacology</i> 56(8) 988–998. DOI:<a href=&quot;https://doi.org/10.1002/jcph.684&quot;>10.1002/jcph.684</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26632101/&quot;>https://pubmed.ncbi.nlm.nih.gov/26632101</a></p></li><li><p>Kumar Puttrevu, S, et al., &amp; Bhatta, RS (2017). Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. <i>Naunyn-Schmiedeberg&#x27;s archives of pharmacology</i> 390(5) 457–470. DOI:<a href=&quot;https://doi.org/10.1007/s00210-017-1339-6&quot;>10.1007/s00210-017-1339-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28190245/&quot;>https://pubmed.ncbi.nlm.nih.gov/28190245</a></p></li><li><p>Ramakrishna, R, et al., &amp; Bhatta, RS (2015). Simultaneous determination of azilsartan and chlorthalidone in rat and human plasma by liquid chromatography-electrospray tandem mass spectrometry. <i>Journal of chromatography. B, Analytical technologies in the biomedical and life sciences</i> 990 185–197. DOI:<a href=&quot;https://doi.org/10.1016/j.jchromb.2015.03.018&quot;>10.1016/j.jchromb.2015.03.018</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25899870/&quot;>https://pubmed.ncbi.nlm.nih.gov/25899870</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09DA09;
